Arthur Allen - KFF Health News

Pharmacy closures by two of the biggest home infusion companies point to grave shortages and dangers for patients who require IV nutrition to survive.

The Vaccines for Children program, which buys more than half the pediatric vaccines in the U.S., may not cover the RSV shot for babies because it’s not technically a vaccine.

A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the CDC to decide the best long-term strategy.

While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.

While sales of its COVID vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.

Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast.

The Rockland County case isn’t expected to cause a major outbreak, but it shows how even this rare disease can pop up in undervaccinated communities.

As the country faces a rise in infections driven by the BA.5 subvariant, about 70% of people 50 and older who got a first booster shot haven't received the recommended second one, according to the CDC.

The drugmaker has the best-selling vaccine to prevent COVID and the most effective drug to treat it. Its success and might have overshadowed the government’s COVID-fighting strategy.

After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?